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Abstract
Background: Super-Seniors are healthy, long-lived individuals who were recruited at age 85 years or older with no
history of cancer, cardiovascular disease, diabetes, dementia, or major pulmonary disease. In a 10-year follow-up, we
aimed to determine whether surviving Super-Seniors showed compression of morbidity, and to test whether the
allele frequencies of longevity-associated variants in APOE and FOXO3 were more extreme in such long-term
survivors.
Methods: Super-Seniors who survived and were contactable were re-interviewed 10 years after initial
characterization. Health and lifestyle were characterized via questionnaire. Geriatric tests including the Timed Up
and Go (TUG), Geriatric Depression Scale (GDS), Instrumental Activities of Daily Living (IADL) and the Mini-Mental
State Exam (MMSE) were administered, and data were compared to results from on average 10 years earlier. As well,
genotype and allele frequencies for SNPs rs7412 and rs429358 in APOE, and rs2802292 in FOXO3 were compared to
the frequencies in the original collection of Super-Seniors and mid-life controls.
Results: Of the 480 Super-Seniors recruited from 2004 to 2007, 13 were alive, contactable, and consented to re-
interview (mean age = 100.1 ± 3.3). Eight of these 13 participants (62%) still met Super-Senior health criteria.
Diseases that occurred in late life were cardiovascular (5 of 13; 38%) and lung disease (1 of 13; 8%). MMSE and IADL
scores declined in the decade between interviews, and GDS and TUG scores increased. The surviving group of
centenarians had a higher frequency of APOE and FOXO3 longevity-associated variants even when compared to the
original long-lived Super-Senior cohort.
Conclusions: Although physical and mental decline occurred in the decade between interviews, the majority of
Super-Seniors re-interviewed still met the original health criteria. These observations are consistent with reports of
compression of morbidity at extreme ages, particularly in centenarians. The increased frequency of longevity-
associated variants in this small group of survivors is consistent with studies that reported genetics as a larger
contributor to longevity in older age groups.
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Background
Maintaining health while aging is important both for
individual quality of life as well as costs to health care
systems. Compression of morbidity refers to a shorter
time between onset of disability and death, and was ori-
ginally postulated to be due to chronic conditions having
a greater capacity to be delayed than survival has to be
increased [1]. A correlation between survival age and
decreased morbidity has been observed, where older age
groups (100–104 years, 105–109 years, and 110–119
years) experienced progressively delayed onset of disease
and physical or cognitive impairment [2].
While the overall incidence of chronic conditions has
been increasing in recent decades [3, 4], compression of
morbidity has been observed in long-lived individuals
[5–8]. As studies of younger groups (e.g., 51–61 years)
[4] did not reveal compression of morbidity, the reduc-
tion in years of disease may be limited to the high end
of the human life span.
The Super-Seniors were collected as a phenotypically
healthy oldest-old group in which to study genetic fac-
tors associated with healthy aging [9, 10]. Super-Seniors
are individuals aged 85 years and older who reported
never being diagnosed with cancer, cardiovascular dis-
ease (CVD), diabetes, dementia, or major pulmonary
disease. Study controls are a population-based compari-
son group of mid-life individuals who resemble a genetic
proxy group for the birth cohort of the Super-Seniors
[10]. The initial collection and characterization of 480
Super-Seniors took place from 2004 to 2007 (Phase 1),
with an additional and ongoing collection initiated in
2014 (Phase 2).
Approximately 10 years after the Phase 1 collection of
Super-Seniors, we attempted to re-contact and re-interview
surviving Super-Seniors. Participants still living would be in
their late nineties or 100 or more, and we hypothesized that
such individuals would have retained much of their health
due to compression of morbidity.
Methods
Research ethics board approval was received from the
joint Clinical Research Ethics Board (REB) of BC Cancer
and the University of British Columbia and from the
REB of Simon Fraser University. All subjects gave writ-
ten informed consent.
Phase 1 collection of Super-Seniors in 2004–2007 [10]
did not include plans to follow participants longitudinally,
so in 2010, Super-Seniors were mailed a letter requesting
permission to re-contact them for future research. In
2016–17, contactable and interested Super-Seniors were
invited for re-interview (Additional file 1: Figure S1).
Super-Seniors were visited in their homes where they
were asked personal and family medical history ques-
tions, and asked to perform geriatric tests as per their
first interview. The Mini-Mental State Exam (MMSE)
[11], Instrumental Activities of Daily Living (IADL) [12],
Geriatric Depression Scale (GDS) [13], and Timed Up
and Go (TUG) [14] were measured and compared to
data from Phase 1 Super-Seniors collected approximately
10 years previously. Differences in scores were analyzed
in one-tailed paired t-tests with the expectation that
MMSE and IADL score would decrease with age, and
that GDS and TUG scores would increase. BMI, HR,
and BP were compared using two-tailed paired t-tests.
Genotype and allele frequencies for SNPs rs7412 and
rs429358 in APOE, and rs2802292 in FOXO3 were
compared to the frequencies in the original Phase 1
Super-Seniors and mid-life controls. Genotypes for these
select variants were extracted from data previously de-
scribed [15]. Statistical analysis was done using R 3.2.2
and JMP 13.
Results
In 2010, we mailed 480 Super-Seniors and an additional
17 borderline phenotype individuals from Phase 1, ex-
cluding 9 for whom the study had been notified of their
death. Twenty-six were reported deceased by relatives,
30 declined (5/30 indicated they were “too sick”), 92
were unable to be contacted (mail was returned to
sender), 246 did not respond, and 94 agreed to be
re-contacted (Additional file 1).
In 2016, we searched for online obituaries and notices
of death, and sent another letter requesting permission
for re-contact to 139 previous non-responders. By 2016,
an additional 107 Super-Seniors were determined to be
deceased through online records or reported to the
study by family members. Of the 138 Super-Seniors
mailed in 2016, 8 were reported deceased, 7 declined (3/
7 indicated they were “too sick”), 26 were unable to be
contacted, 89 did not respond, and 9 agreed to be
re-contacted.
Twenty-eight Super-Seniors were invited for interview.
Of those, 13 accepted and completed the re-interview; 2
declined, 10 could not be reached, 1 died, and 2 were
reported by relatives to be too ill to be interviewed. The
13 Super-Seniors re-interviewed in 2017 included 10
women and 3 men aged 96–106 (mean = 100.1, SD = 3.3),
who were all of European ancestry.
The two Super-Seniors who were too ill to be inter-
viewed included a 100-year-old woman reported by a
family member to be confused much of the time, not
doing very well, and feeling sick and tired. The other
was a 106-year-old woman reported by a family member
to be bedridden and mostly non-responsive. Deterior-
ation reportedly took place around age 100–101 when
she began suffering episodes of dementia. Other than
dementia, she had no health problems and was very
mobile until age 103.
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Re-interviews took place 9.3–12.1 years (mean = 10.9,
SD = 0.9) after the initial interviews (Additional file 2).
Of the 13 Super-Seniors who were re-interviewed, 8 still
met the health criteria for being a Super-Senior, 5
women and all 3 of the men. Of the 5 Super-Seniors
who did not meet the criteria for enrollment at the time
of their re-interview in 2017, all had developed CVD:
two had strokes (at ages 97 and 100, respectively), two
had heart conditions (mitral valve issue [age unknown]
and pacemaker [at age 99]), and one who was inter-
viewed at age 96 had a minor heart attack, minor
strokes, and COPD.
Of the 13 Super-Seniors re-interviewed, 6 were never
smokers and the remaining 7 had quit. The quitters
smoked between 5 and 51 years (mean = 29.7, SD = 16.0).
Of note, the individual who had COPD was a housewife
who never smoked.
Descriptive statistics and geriatric test scores are
shown in Table 1 and Fig. 1. MMSE mean scores de-
clined from 28.7 (SD = 1.4) to 23.8 (SD = 4.2) points out
of a possible 30, a mean decline of 4.9 points (t = − 4.5,
P = 0.00036). IADL scores declined from 22.3 (SD = 1.5)
to 15.6 (SD = 6.1) out of a possible 23 points, a mean
decline of 6.7 points (t = − 3.7, P = 0.0016). GDS scores
increased from 0.5 (SD = 1.0) to 2.2 (SD = 2.5), a mean
difference of 1.7 points (t = 2.6, P = 0.011). TUG scores
increased from 9.8 (SD = 2.1) to 32.0 (28.0) seconds, a
mean difference of 22.2 s (t = 2.9, P = 0.0070). Among
the 9 individuals who did not use a walker as an aid, the
mean TUG time was 17.9 s (SD = 5.3).
There was no significant difference in BMI, heart rate,
or blood pressure (BP) between the two interviews. Eight
participants were taking BP medication at the time of
both interviews, 4 were not taking any BP medication at
either interview, and one man had discontinued taking
BP medication by the time of the second interview.
Genotyping in re-interviewed Super-Seniors was not
available for one participant in APOE and two partici-
pants in FOXO3. Genotype counts and minor allele fre-
quency (MAF) values are shown in Table 2. Genotyping
of Phase 1 Super-Seniors and controls was used for
comparison [15].
Discussion
We attempted to re-contact Super-Seniors 9–12 years
after they were enrolled. As expected for an older group,
even one as healthy as the Super-Seniors, most partici-
pants had passed away within this time frame. We could
confirm that at least 17 of the original 480 Super-Seniors
were still living.
Eight of the 13 individuals re-interviewed in 2017
(54%) still met the criteria for being a Super-Senior;
among the individuals who no longer met the
Super-Senior criteria, most had developed their health
problems in the previous 3 years. The most common
diseases in the group were CVD (5 of 13; 38%), and lung
disease (1 of 13; 8%). According to the US National
Center for Health Statistics from 2012 to 2013, 29.8% of
Americans aged 65 years and older reported having heart
disease, and 18.4% reported having cancer [3]. As well,
Table 1 Characteristics of Super-Seniors at two interviews approximately 10 years apart
Super-Seniors
Study
Re-contacts P-value
First Interview Second Interview 1st and 2nd
interviewsYear 2004–2007 2004–2007 2016–2017
N 480 13
Male 155 3
Female 325 10
Age mean (SD) years 88.5 (2.9) 89.3 (2.7) 100.1 (3.3)
Age range 85–105 85–94 96–106
Years between interviews (SD) – 10.9 (0.9)
BMI mean (SD) kg/m2 24.5 (3.9) 25.8 (4.0) 23.4 (3.9)a 0.071
BP mean systolic (SD) mmHg 152 (21)a 142 (16)a 120 (35) 0.077
BP mean diastolic (SD) mmHg 78 (11)a 72 (9)a 72 (10) 0.980
Heart rate (SD) beats per min 70 (11)a 67 (9)a 74 (11) 0.120
MMSE mean (SD) 28.3 (1.7) 28.7 (1.4) 23.8 (4.2) < 0.001
IADL mean (SD) 21.4 (3.5) 22.3 (1.5) 15.6 (6.1) 0.002
GDS mean (SD) 1.5 (1.8) 0.5 (1.0) 2.2 (2.5) 0.011
TUG mean (SD) seconds 12.3 (4.3) 9.8 (2.1) 32.0 (28.0) 0.007
aBlood pressure and heart rate were not available for all initial interviews. Super-Seniors Study blood pressure n = 298, heart rate n = 290. Re-contacts first
interview blood pressure n = 12, heart rate n = 12. Re-contacts second interview BMI n = 12
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in a cohort of men born in 1913 and followed to age
100, CVD was the most common cause of death after
the 80 years of age [16].
Although we cannot compare relative morbidity time
between groups, our observations that 8/13 of the survi-
vors were still “Super”, and that the 5/13 with chronic
diseases developed them in their late 90s or early 100 s,
these observations suggest that compression of morbid-
ity is occurring in these individuals. Compression of
morbidity has been suggested in other studies of
long-lived people including the New England Centenar-
ian Study, where they found that between nonagenar-
ians, centenarians, semicentenarians (105–109 years),
and supercentenarians (110–119 years), there was a later
onset of major age-related diseases as the age group in-
creased [2]. As well, among 15 Okinawa supercentenar-
ians (age at death 110–112) it was found that they had
delayed clinically apparent diseases until very late in life,
with 83% not reporting clinically apparent disease until
105 years or later [17].
Fig. 1 Super-Senior geriatric test scores at the first and second interviews approximately 10 years apart. MMSE = Mini-Mental State Exam, GDS =
Geriatric Depression Scale, IADL = Instrumental Activities of Daily Living, TUG = Timed Up and Go
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A German health insurance study also found that
there was a lower prevalence of comorbidities among
those who died as centenarians than those who died in
their 80s [8]. Likewise, while 8 Super-Seniors were still
disease free, 5 had one disease, and only one individual
had co-morbidities.
We compared the current geriatric test scores of the
Super-Seniors to their initial interview scores. MMSE
and IADL scores declined in the decade between inter-
views, while GDS and TUG scores increased. For all four
tests, the standard deviation increased from the first to
second interviews indicating that there was a wider
range of physical and cognitive function as the surviving
participants aged.
Mean MMSE scores decreased from 28.7 to 23.8 points.
Although this is a test of cognitive function, at least a por-
tion of the decreased score was due to visual and/or hear-
ing impairment, which affected the participant’s ability to
answer some questions. At the time of the second inter-
view, two individuals were legally blind, another was un-
able to see the images, and three were hard of hearing.
Vision impairment for these individuals was not noted at
the time of the first interview. It is worth noting however,
that the one perfect score among the re-interviews was by
a 102-year-old woman with macular degeneration. The
traditional cut-off score for being “normal” and without
cognitive impairment is 24, however a study of highly edu-
cated Caucasians found that a cut-off of 24 resulted in a
moderate sensitivity (0.66) and very high specificity (0.99),
whereas a cut-off score of 27 achieved a balance between
sensitivity (0.89) and specificity (0.91) [18]. At the second
interview, the Super-Seniors mean score almost meets the
traditional 24-point cut-off. Individually however, the
range of scores decreased from 25 to 30 points to 17–30
points indicating that at while some Super-Seniors have
retained their cognitive function, others are experiencing
increasing impairment.
All geriatric scores declined with age, with the second
interview showing that the Super-Seniors had a mean
higher depression score, decreased mobility, and were per-
forming fewer daily tasks as measured by the IADL. Their
GDS score, however, was still a mean of 2.2 points, below
the value of ≥5 that has been indicated as an appropriate
cut-off score for depression [19]. As well, although the
TUG time increased from a mean of 9.8 to 32.0 s, 4 indi-
viduals used a walker as a mobility aid and one used a
cane. The mean TUG time for individuals without a
walker was 17.9 s. Although there is no specific standard
for TUG time, it has been found that physical fitness indi-
cators such as the TUG are associated with successful
aging [20]. It has also been suggested that among adults
65 years and older with a similar disease burden, those
who were more physically vigorous experienced compres-
sion of morbidity and lived longer [21]. A decreased IADL
score indicates that they are performing fewer tasks inde-
pendently; however, and in a study of individuals 90 years
and older, regularly needing help was found to be a signifi-
cant predictor of mortality [22].
The Okinawa centenarian study found that both BMI
and BP decreased with age as individuals transitioned
from centenarians to supercentenarians [17]. Longitudin-
ally, when they followed individuals from age groups 99–
103 years, to 104–107 years, to 108–111 years, their BMI
decreased from 21.47, to 18.81, to 17.43, respectively. As
well, their BP (systolic/diastolic) decreased from 142/74
mmHg, to 128/70mmHg, to 119/64mmHg. Similarly, fol-
lowing the Super-Seniors from ages 85–94 years, to 96–
106 years, we saw a non-significant decrease in BMI from
25.8 (SD = 4.0) to 23.4 (SD = 3.9). Systolic BP of the
Super-Seniors decreased from 142mmHg (SD = 16) to
120mmHg (SD = 35) and diastolic BP remained the same
at 72mmHg (SD = 9) and 72mmHg (SD = 10). Interest-
ingly, the re-interviewed Super-Seniors had lower values
at their initial interviews for both their systolic and dia-
stolic BP than the mean of the overall Phase 1
Super-Seniors cohort, 152/78mmHg (Table 1). Both the
values and the decline exhibited in Super-Seniors are con-
sistent with what was observed in the Okinawa study.
APOE and FOXO3 are the two loci most consistently
associated with longevity, reviewed by: [23–25]. APOE
has been found in genome-wide scans and cohort stud-
ies of longevity; the minor allele of rs7412 is sometimes
Table 2 Genotype comparison between Super-Senior survivors, and the original Phase 1 collection of Super-Seniors and controls
Re-interviewed Super-Seniors (n = 13) All Super-Seniors (n = 466) Controls (n = 421)
Genotypes MAF Genotypes MAF Genotypes MAF
APOE rs7412 TT × 1
TC × 1
CC × 10
0.125 TT × 6
TC × 69
CC × 363
0.092 TT × 3
TC × 57
CC × 352
0.076
APOE rs429358 CC × 0
CT × 2
TT × 10
0.083 CC × 4
CT × 84
TT × 350
0.105 CC × 10
CT × 110
TT × 293
0.157
FOXO3 rs2802292 GG × 0
GT × 9
TT × 2
0.409 GG × 55
GT × 226
TT × 162
0.379 GG × 47
GT × 189
TT × 166
0.352
MAF minor allele frequency
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associated with longevity, and the minor allele of
rs429358 is reliably associated with increased mortality
[26–31]. Together these two variants determine APOE2/
3/4 haplotypes. At rs7412, the re-interviewed Super-Se-
niors had a MAF 0.125, compared to MAF 0.092 in all
Phase 1 Super-Seniors, and MAF 0.076 in mid-life con-
trols. At rs429358, the re-interviewed Super-Seniors had
MAF 0.083, compared to 0.105 in all Super-Seniors, and
0.157 in controls. This demonstrates that among these
elite survivors, Super-Seniors who survived another ~ 10
years, there appears to be a slightly higher frequency of
the favorable longevity allele of rs7412, and a lower
frequency of the deleterious mortality and AD-related
allele of rs429358, even when compared to the original
group of Phase 1 Super-Seniors.
In FOXO3, the G allele of rs2802292 has been associ-
ated with longevity [32]. 81.2% re-interviewed
Super-Seniors carried at least one G allele, compared to
63.4% in all Phase 1 Super-Seniors and 58.7% of con-
trols. Previously we did not find an association of
rs2802292 with the Super-Senior phenotype, compared
to mid-life controls, but we do see an apparent enrich-
ment among this small group of survivors. This possible
association may be stronger at more advanced ages, or it
could be an artifact of the very small sample size.
It is important to note that this study is limited by very
small sample size. Observations made in this small group
of individuals may not be typical of centenarians in gen-
eral. Partially contributing to this low number, however, is
the fact that the majority of Super-Seniors were either not
contactable or did not respond and, while most will have
passed away, we do not know the exact number. As well,
although the average age at recruitment was 88.5 years,
some Super-Seniors were already in or near their 100 s at
the time of initial recruitment and would therefore be less
likely to be alive 10 years later. Given that the average life-
span for the Super-Seniors birth cohort (mean birth year
1916) was approximately 57 years, the 13 Super-Seniors
who were re-interviewed represent a small but elite group
who delayed disease onset until very late in life, and
possibly exhibit compression of morbidity.
Conclusions
Although physical and mental decline occurred in the
decade between interviews, the majority of Super-Se-
niors re-interviewed still met the original health criteria.
These observations are consistent with reports of com-
pression of morbidity at extreme ages, particularly in
centenarians [5, 7, 8]. The increased frequency of
longevity-associated variants in this small group of
survivors is consistent with studies that reported gen-
etics as a larger contributor to longevity in older age
groups [33, 34].
Additional files
Additional file 1: Follow-up of participants in the Super-Seniors Study
flow chart. (PDF 39 kb)
Additional file 2: Study dataset. (XLSX 38 kb)
Abbreviations
BMI: Body mass index; BP: Blood pressure; COPD: Chronic obstructive
pulmonary disease; CVD: Cardiovascular disease; GDS: Geriatric Depression
Scale; IADL: Instrumental Activities of Daily Living; MAF: Minor allele
frequency; MMSE: Mini-Mental State Exam; REB: Research ethics board;
SD: Standard deviation; SNP: Single nucleotide polymorphism; TUG: Timed
up and go
Acknowledgements
We thank Monique Sekhon and Olivia Aguiar who conducted the second
interviews.
Funding
This work was carried out with funding from the Lotte and John Hecht
Memorial Foundation. LCT was supported by a Doctoral Award from the
Canadian Institutes for Health Research. The funding agencies did not have
any role in the design of the study, collection, analysis, interpretation of data,
and in writing the manuscript.
Availability of data and materials
The datasets used and analysed during the current study available from the
corresponding author on reasonable request.
Authors’ contributions
LCT: study concept and design, analysis and interpretation of data, drafting
and final approval of manuscript. DS: acquisition of subjects and data,
revision and final approval of manuscript. ARBW: study concept and design,
revision and final approval of manuscript. All authors read and approved the
manuscript.
Ethics approval and consent to participate
Research ethics board approval was received from the joint Clinical Research
Ethics Board (REB) of BC Cancer and the University of British Columbia and
from the REB of Simon Fraser University. All subjects gave written informed
consent.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 2 August 2018 Accepted: 19 February 2019
References
1. Aging FJF, Death N. The compression of morbidity. N Engl J Med. 1980;
303(3):245–50.
2. Andersen SL, Sebastiani P, Dworkis DA, Feldman L, Perls TT. Health span
approximates life span among many supercentenarians: compression of
morbidity at the approximate limit of life span. J Gerontol A Biol Sci Med
Sci. 2012;67(4):395–405.
3. National Center for Health Statistics (US). Health, United States, 2014: With
Special Feature on Adults Aged 55–64. Hyattsville (MD): National Center for
Health Statistics (US). 2015; Report No.: 2015–1232. https://www.ncbi.nlm.
nih.gov/books/NBK45497/.
4. Beltran-Sanchez H, Jimenez MP, Subramanian SV. Assessing morbidity
compression in two cohorts from the health and retirement study. J
Epidemiol Community Health. 2016;70(10):1011–6.
Tindale et al. BMC Geriatrics           (2019) 19:58 Page 6 of 7
5. Ismail K, Nussbaum L, Sebastiani P, Andersen S, Perls T, Barzilai N, et al.
Compression of morbidity is observed across cohorts with exceptional
longevity. J Am Geriatr Soc. 2016;64(8):1583–91.
6. Christensen K, McGue M, Petersen I, Jeune B, Vaupel JW. Exceptional
longevity does not result in excessive levels of disability. Proc Natl Acad Sci
U S A. 2008;105(36):13274–9.
7. Kheirbek RE, Fokar A, Shara N, Bell-Wilson LK, Moore HJ, Olsen E, et al.
Characteristics and incidence of chronic illness in community-dwelling
predominantly male U.S. veteran centenarians. J Am Geriatr Soc. 2017;65(9):
2100–6.
8. Gellert P, von Berenberg P, Oedekoven M, Klemt M, Zwillich C, Horter S, et
al. Centenarians differ in their comorbidity trends during the 6 years before
Death compared to individuals who died in their 80s or 90s. J Gerontol A
Biol Sci Med Sci. 2018;73(10):1357–62.
9. Halaschek-Wiener J, Amirabbasi-Beik M, Monfared N, Pieczyk M, Sailer C,
Kollar A, et al. Genetic variation in healthy oldest-old. PLoS One. 2009;
4(8):e6641.
10. Halaschek-Wiener J, Tindale LC, Collins JA, Leach S, McManus B, Madden K,
et al. The super-seniors study: phenotypic characterization of a healthy 85+
population. PLoS One. 2018;13(5):e0197578.
11. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical
method for grading the cognitive state of patients for the clinician. J
Psychiatr Res. 1975;12(3):189–98.
12. Lawton MP, Brody EM. Assessment of older people: self-maintaining and
instrumental activities of daily living. Gerontologist. 1969;9(3):179–86.
13. Sheikh JI, Yesavage JA. Geriatric depression scale (GDS) recent evidence and
development of a shorter version. Clin Gerontol. 1986;5:165–73.
14. Podsiadlo D, Richardson S. The timed "up & go": a test of basic functional
mobility for frail elderly persons. J Am Geriatr Soc. 1991;36(2):142–8.
15. Tindale LC, Leach S, Spinelli JJ, Lipid B-WA. Alzheimer’s disease genes
associated with healthy aging and longevity in healthy oldest-old.
Oncotarget. 2017;8(13):20612–21.
16. Wilhelmsen L, Dellborg M, Welin L, Svardsudd K. Men born in 1913 followed
to age 100 years. Scand Cardiovasc J. 2015;49(1):45–8.
17. Willcox DC, Willcox BJ, Wang N, He Q, Rosenbaum M, Suzuki M. Life at the
extreme limit: phenotypic characteristics of supercentenarians in Okinawa. J
Gerontol A Biol Sci Med Sci. 2008;63(11):1201–8.
18. O'Bryant SE, Humphreys JD, Smith GE, Ivnik RJ, Graff-Radford NR, Petersen
RC, et al. Detecting dementia with the mini-mental state examination in
highly educated individuals. Arch Neurol. 2008;65(7):963–7.
19. Marc LG, Raue PJ, Bruce ML. Screening performance of the 15-item geriatric
depression scale in a diverse elderly home care population. Am J Geriatr
Psychiatry. 2008;16(11):914–21.
20. Lin PS, Hsieh CC, Cheng HS, Tseng TJ, Su SC. Association between physical
fitness and successful Aging in Taiwanese older adults. PLoS One. 2016;
11(3):e0150389.
21. Sanders JL, Arnold AM, Hirsch CH, Thielke SM, Kim D, Mukamal KJ, et al.
Effects of disease burden and functional adaptation on morbidity and
mortality on older adults. J Am Geriatr Soc. 2016;64(6):1242–9.
22. Jylhä M, Hervonen A. Functional status and need of help among people
aged 90 or over: a mailed survey with a total home-dwelling population.
Scand J Public Health. 1999;27(2):106–11.
23. Brooks-Wilson AR. Genetics of healthy aging and longevity. Hum Genet.
2013;132(12):1323–38.
24. Christensen K, Johnson TE, Vaupel JW. The quest for genetic
determinants of human longevity: challenges and insights. Nat Rev
Genet. 2006;7(6):436–48.
25. Wheeler HE, Kim SK. Genetics and genomics of human ageing. Philos Trans
R Soc Lond Ser B Biol Sci. 2011;366(1561):43–50.
26. Schupf N, Barral S, Perls T, Newman A, Christensen K, Thyagarajan B, et
al. Apolipoprotein E and familial longevity. Neurobiol Aging. 2013;34(4):
1287–91.
27. Frisoni GB, Louhija J, Geroldi C, Trabucchi M. Longevity and the e2 allele of
apolipoprotein E: the Finnish centenarians study. J Gerontol A Biol Sci Med
Sci. 2001;56(2):M75–8.
28. Ryu S, Atzmon G, Barzilai N, Raghavachari N, Suh Y. Genetic landscape of
APOE in human longevity revealed by high-throughput sequencing. Mech
Ageing Dev. 2016;155:7–9.
29. Schächter F, Faure-Delanef L, Guénot F, Rouger H, Froguel P, Lesueur-Ginot
L, et al. Genetic associations with human longevity at the APOE and ACE
loci. Nat Genet. 1994;6(1):29–32.
30. Rea IM, Mc Dowell I, McMaster D, Smye M, Stout R, Evans A, et al.
Apolipoprotein E alleles in nonagenarian subjects in the BELFAST elderly
longitudinal free-living ageing study (BELFAST). Mech Ageing Dev. 2001;
122(13):1367–72.
31. Bennati E, Murphy A, Cambien F, Whitehead AS, Archbold GP, Young IS, et
al. BELFAST centenarians: a case of optimised cardiovascular risk? Curr
Pharm Des. 2010;16(7):789–95.
32. Willcox BJ, Donlon TA, He Q, Chen R, Grove JS, Yano K, et al. FOXO3A
genotype is strongly associated with human longevity. Proc Natl Acad Sci U
S A. 2008;105(37):13987–92.
33. Murabito JM, Yuan R, Lunetta KL. The search for longevity and healthy
aging genes: insights from epidemiological studies and samples of long-
lived individuals. J Gerontol A Biol Sci Med Sci. 2012;67(5):470–9.
34. Newman AB, Murabito JM. The epidemiology of longevity and exceptional
survival. Epidemiol Rev. 2013;35:181–97.
Tindale et al. BMC Geriatrics           (2019) 19:58 Page 7 of 7
